- Home >
- Clinicals Trials >
- MOST Plus
Retour à la liste des essais cliniques
MOST Plus
My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors
- Ouvert à Paris depuis le : 24/09/2014
- Public cible : Adult
- Phase : Phase II
Description de l'essai
This trial evaluates the efficacy of 4 oral targeted therapies (everolimus, sorafenib, pazopanib, and nilotinib) in patients with any kind of cancer whose harbour the matching targets of these drugs.
Url of the trialInvestigateur principal
